Oct 2026
Reversal of T1D and Rapid Reduction of β-Cell Stress by IL-10-Dependent MDSCs Induced by TLR4-Ab.
ARTICLE HIGHLIGHTS Therapy with IgG3 Toll-like receptor 4 (TLR4)/myeloid differentiation factor 2 (MD2) agonistic antibody (TLR4-Ab) is a novel approach to type 1 diabetes (T1D) immunotherapy that targets the innate immune system by inducing immunoregulatory myeloid-derived suppressor cells (MDSCs). We sought to define...
Nicolle K. Martin, Luke S. Heuer, Ixchel M. Urbano et al.
· Diabetes · 0 citations